Friends

Login

Service

Sally Church

Interested in Pharma, Biotech, Science and cancer... Find me at http://www.pharmastrategyblog.com also love food, wine, the NFL and cricket. Hi!
Sally Church
albotas: Watch This Girl Build Her Own Prosthetic Leg Out Of LEGO Pieces It’s awesome watching this girl scavenge for all the right pieces (a feeling I’m sure we’re all familiar with), and become increasingly delighted at her progress. See for yourself. The uploader, AmputeeOT, says: Someone in my research lab jokingly suggested I make a... - http://maverickny.tumblr.com/post...
from
Sally Church
ASH 2012 update on ARRY-520 in multiple myeloma - http://pharmastrategyblog.com/2013...
from
Sally Church
Will biomarkers revolutionalise treatment with tivozanib? - http://pharmastrategyblog.com/2013...
from
Sally Church
ASCO GU update on tivozanib in advanced clear cell renal cancer - http://pharmastrategyblog.com/2013...
from
Sally Church
Tumor Lysis Syndrome – what is it and why is it important in cancer research? - http://pharmastrategyblog.com/2013...
from
Sally Church
Making a difference in Advanced Prostate Cancer – an interview with Bertrand Tombal - http://pharmastrategyblog.com/2013...
from
Sally Church
Making a difference in pancreatic cancer – an interview with Dr Hedy Lee Kindler - http://pharmastrategyblog.com/2013...
from
Sally Church
Will ASCO GI herald a new era for pancreatic cancer? - http://pharmastrategyblog.com/2013...
from
Sally Church
Effectively targeting KRAS in lung cancer with a MEK inhibitor - http://pharmastrategyblog.com/2012...
from
Sally Church
Time to rethink cancer clinical trials strategy? - http://pharmastrategyblog.com/2012...
from
Sally Church
Zaltrap – a simple dosing error or not? - http://pharmastrategyblog.com/2012...
from
Sally Church
Update on KRAS in pancreatic cancer - http://pharmastrategyblog.com/2012...
from
Sally Church
Prospect of Abraxane in Pancreatic Cancer excites ESMO 2012 - http://pharmastrategyblog.com/2012...
from
Sally Church
Update on bavituximab in non-squamous lung cancer - http://pharmastrategyblog.com/2012...
from
Sally Church
ASCO 2012 Update 2: Overcoming resistance in metastatic melanoma - http://pharmastrategyblog.com/2012...
from
Sally Church
A surfeit of riches in CLL and NHL: on bruton kinase and PI3K delta inhibitors - http://pharmastrategyblog.com/2012...
from
Sally Church
ASCO 2012 Update 1: Advanced Lung Cancer - http://pharmastrategyblog.com/2012...
from
Sally Church
Interested in the PI3K-AKT-mTOR pathway in cancer research? - http://pharmastrategyblog.com/2012...
from
Sally Church
Aggregating the 2012 ASCO tweets - http://pharmastrategyblog.com/2012...
from
Sally Church
Update on advanced prostate cancer including enzalutamide (MDV3100) and abiraterone - http://pharmastrategyblog.com/2012...
from
Sally Church
Stunning data with dabrafenib (BRAFV600E) in metastatic melanoma and brain metastases - http://pharmastrategyblog.com/2012...
from
Sally Church
Reflections of a Medical Oncologist on AACR 2012 - http://pharmastrategyblog.com/2012...
from
Sally Church
ASCO 2012 Preview – Highlights of key data emerging from Chicago - http://pharmastrategyblog.com/2012...
from
Sally Church
ASCO 2012 Acronym Mania! - http://pharmastrategyblog.com/2012...
from
Sally Church
Ribonucleases (RNase) – clinical applications for cancer therapy - http://pharmastrategyblog.com/2012...
from
Sally Church
Ribonucleases (RNase) what are they and why are they relevant to cancer? - http://pharmastrategyblog.com/2012...
from
Sally Church
Highlights of AACR 2012 – Part 3 - http://pharmastrategyblog.com/2012...
from
Sally Church
Highlights of AACR 2012 – Part 2 - http://pharmastrategyblog.com/2012...
from
Sally Church
Highlights of AACR 2012 – Part 1 - http://pharmastrategyblog.com/2012...
from
Sally Church
American Society for Cancer Research Meeting 2012 - http://pharmastrategyblog.com/2012...
from
Sally Church
On adaptive mechanisms of crizotinib resistance in ALK-positive lung cancer - http://pharmastrategyblog.com/2012...
from
Sally Church
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR : Nature : Nature Publishing Group - http://www.nature.com/nature...
from
Colon cancer patients harbouring BRAF(V600E) oncogenic lesion have poor prognosis and show only a very limited response to vemurafenib, despite it being effective for melanoma. Why? - Sally Church
« Prev Next »